SAI - Detailed view

XIMLUCI 2.3 mg/0.23ml m Filterna Durchstf 0.23 ml

Drug

Name

Ximluci, Injektionslösung

Field of application

Exsudative altersbezogene Makuladegeneration, Visusverlust durch diabetisches Makulaödem, Visusverlust durch Makulaödem infolge eines retinalen Venenverschlusses und durch choroidale Neovaskularisation infolge pathologischer Myopie, aktive, den Visus beeinträchtigende choroidale Neovaskularisation, mässig schwere bis schwere NPDR bzw. PDR, Frühgeborenen-Retinopathie.

ATC

S01LA04 - RANIBIZUMAB

11.99.0. – various

Use

HAM – Human medicine

pharmaceutical form

LSINJ – Solution for injection

Remedy code

BT – biological medicines

Dispensing categories

B – Dispensed on prescription by a physician or veterinarian (B)

Authorisation status

Z – approved

Authorisation number

69578

Basic authorisation number

57664

Initial registration date

7/22/2024

Expiry date

7/21/2029

Dosage strength

Name

Ximluci 10 mg/ml, Injektionslösung

Field of application

Dosage strength number

Authorisation status

Z – approved

Package

GTIN**

7680695780017

Trade status*

In trade from / since 7/22/2024

Status

A/R – Authorised / referenced

Package size

1 vial(s)

Package code

001

Authorisation status

Z – approved

Declaration

Component

Active substance

10 mg ranibizumabum

Excipient

trehalosum dihydricum
histidinum
histidini hydrochloridum monohydricum
polysorbatum 20
aqua ad iniectabile

Spezialitätenliste***

Status

Date of deletion

Compulsory until

Public price (CHF)

544.60

Limitation points

None

Limitation

Yes

SB Deductible

10%

Generic

Authorisation holder

GLN**

7601001394834

Address

Spirig HealthCare AG
Industriestrasse 30
4622 Egerkingen (SO)

Date of revision of the text

8/1/2025

Information for prof.

Leaflet

Report error

Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.